Seres Therapeutics (MCRB) Misses Q2 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Seres Therapeutics (MCRB) Misses Q2 EPS by 16c

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

August 3, 2021 7:00 AM EDT

SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021

SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits

Microbiome analyses from SER-287 Phase 2b ulcerative colitis study anticipated in H2 2021

Continued clinical development progress with SER-155 and SER-301, next-generation rationally designed pipeline candidates

Conference call at 8:30 a.m. ET today

CAMBRIDGE,... More